Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
  • Patent number: 9981027
    Abstract: The present invention provides an agent for controlling colibacillosis including a fusion protein comprising a subunit of Shiga toxin and a subunit of Escherichia coli heat-labile toxin.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: May 29, 2018
    Assignees: IDEMITSU KOSAN CO., LTD., NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE
    Inventors: Kazutoshi Sawada, Takeshi Matsui, Eiji Takita, Takashi Hamabata, Toshio Sato
  • Patent number: 9981020
    Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 29, 2018
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Kamel Khalili, Wenhui Hu
  • Patent number: 9968653
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: May 15, 2018
    Assignees: Regeneron Pharmaceuticals, Inc., University Health Network
    Inventors: Lisa Arleen Purcell Ngambo, Sarah J. Higgins, Kevin C. Kain
  • Patent number: 9969804
    Abstract: Antibodies (e.g., isolated antibodies) that specifically bind to human integrin ?8 and inhibit adhesion of latency associated peptide (LAP) to ?v?8 are provided. In some embodiments, the antibody cross-reacts with mouse integrin ?8. In some embodiments, the antibody blocks TGFJ3 activation. In some embodiments, the antibody antagonizes binding of LAP to ??8 with an IC50 below 5 nM.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: May 15, 2018
    Assignee: The Regents of the University of California
    Inventors: Dean Sheppard, Amha Atakilit, Neil Cowan Henderson
  • Patent number: 9951104
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: April 24, 2018
    Assignee: Serpin Pharma, LLC
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Patent number: 9951105
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: April 24, 2018
    Assignee: BIONIZ, LLC
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Patent number: 9945868
    Abstract: The invention comprises a method for determining degree of modified potency of a bipathic medicament. A bipathic medicine is a medicament comprising a therapeutic component and a homeopathic component, wherein the homeopathic component has some physical, chemical or biological affect on the therapeutic component and/or the pharmacological efficacy thereof. An analytical measurement of at least one characteristic parameter of the therapeutic form is made prior to its interaction with the activated-potentiated form. The same analytical measurement(s) are made and after interaction between the therapeutic and activated-potentiated forms. This data is used to confirm the presence of any modified potency is caused by the presence of molecular form in the activated-potentiated form.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: April 17, 2018
    Inventor: Oleg Iliich Epshtein
  • Patent number: 9945798
    Abstract: The invention comprises a method for determining degree of modified potency of a medicament. A medicine is a medicament comprising a therapeutic component and a homeopathic, i.e., activated-potentiated, component, wherein the activated-potentiated component has some physical, chemical or biological affect on the therapeutic component and/or the pharmacological efficacy thereof. The therapeutic component is biologically related to the starting substance of the homeopathic component. An analytical measurement of at least one characteristic parameter of the therapeutic form is made prior to its interaction with the activated-potentiated form. The same analytical measurement(s) are made and after interaction between the therapeutic and activated-potentiated forms. This data is used to confirm the presence of any modified potency is caused by the presence of molecular form in the activated-potentiated form.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: April 17, 2018
    Assignee: Oleg Illiich Epshtein
    Inventor: Oleg Iliich Epshtein
  • Patent number: 9943596
    Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: April 17, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jimin Lee, Bo Gyou Kim, Seungja Oh, Kyung Ah Kim, Powei Lin, Saet Byoul Lee
  • Patent number: 9939452
    Abstract: This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta_11 N-terminal site, i.e. A?11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: April 10, 2018
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Marc Hubert Mercken, Marc Maria Pierre Vandermeeren
  • Patent number: 9926380
    Abstract: The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: March 27, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jeffrey Molldrem, Anna Sergeeva
  • Patent number: 9926607
    Abstract: The present invention provides breast cancer markers based on RECQL mutations, and related methods, uses, agents, and kits. The invention includes methods for determining the susceptibility of a subject to developing breast cancer, and methods for detecting, diagnosing, treating, and predicting responses to treatment for breast cancer.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: March 27, 2018
    Assignee: Women's College Hospital
    Inventor: Mohammad R. Akbari
  • Patent number: 9925261
    Abstract: Disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1- are also disclosed herein for the treatment of pre-eclampsia or eclampsia.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: March 27, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: S. Ananth Karumanchi, Sharon Maynard, Vikas P. Sukhatme
  • Patent number: 9925248
    Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: March 27, 2018
    Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Kamel Khalili, Wenhui Hu
  • Patent number: 9890144
    Abstract: Compounds and embodiments of a method for treating and/or preventing autoimmune diseases are disclosed. The method includes administering to a subject having an autoimmune disease, such as an inflammatory bowel disease, a therapeutically effective amount of a compound according to formula I wherein X and Y independently are O or NR1; each R1 is independently H or C1-C6 alkyl; ring A is aryl; each R2 independently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two R2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; R3 and R4 independently are H or C1-C6 alkyl; and R5 is halo, cyano, or C1-C6 alkyl.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: February 13, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
  • Patent number: 9879085
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: January 30, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber, Martin Lanzendoerfer
  • Patent number: 9868777
    Abstract: The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: January 16, 2018
    Assignees: Merck Sharp & Dohme Corp., Board of Regents of the University of Texas System
    Inventors: Tong-Ming Fu, Dai Wang, Zhiqiang An
  • Patent number: 9850310
    Abstract: Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 26, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Francois Gaudet, Jennifer F. Nemeth, Ricardo Attar, Benjamin C. Harman, Yingzhe Li, Jinquan Luo, Ronan McDaid, Steven C. Pomerantz, Susan H. Tam, Alexey Teplyakov, John Wheeler, Sheng-Jiun Wu
  • Patent number: 9822418
    Abstract: This invention relates to a method of diagnosing a subject as having and/or being a carrier for infantile myofibromatosis. This method involves providing an isolated biological sample from a subject; contacting the sample with one or more reagents suitable for detecting the presence or absence of one or more mutations in PDGFRB and/or NOTCH3; detecting, in the sample, the presence or absence of the one or more mutations in PDGFRB and/or NOTCH3 based on said contacting; and diagnosing the subject as having and/or being a carrier for infantile myofibromatosis based on said detecting, where the presence of the one or more mutations in PDGFRB and/or NOTCH3 indicates the subject has a mutation that causes infantile myofibromatosis. Also disclosed is a method of treating a subject having infantile myofibromatosis and a method of preventing or treating symptoms associated with infantile myofibromatosis.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: November 21, 2017
    Assignees: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: John A. Martignetti, Hakon Hakonarson, Lifeng Tian
  • Patent number: 9822173
    Abstract: The present application is directed to heterodimeric antibodies and methods of use.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: November 21, 2017
    Assignee: AMGEN INC.
    Inventors: Gunasekaran Kannan, Monica Florio, Zhi Liu, Wei Yan
  • Patent number: 9809636
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 7, 2017
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
  • Patent number: 9809648
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: November 7, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Patent number: 9796984
    Abstract: The present invention relates to genes, proteins and methods comprising molecules that alter amino acid levels. In one embodiment, the present invention relates to altering guanidino substrate hydrolysis activities in plants, arthropods and microorganisms using molecules within the arginase family and other molecules that alter an amino acid levels. In ones embodiment, the present invention relates to altering threonine substrate deamination and dehydration activities in plants, arthropods and microorganisms using molecules within the threonine deaminase family and other molecules that alter amino acid levels. In one embodiment, the present invention relates to using genes, proteins and methods comprising arginase or threonine deaminase for altering the pathophysiology of plants, arthropods and microorganisms. In a preferred embodiment, the present invention relates to altering guanidino substrate hydrolysis activity in plants, arthropods, and microorganisms using arginase.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: October 24, 2017
    Assignee: Board of Trustees of Michigan State University
    Inventors: Gregg A. Howe, Hui Chen
  • Patent number: 9790277
    Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, H7CR, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: October 17, 2017
    Assignees: The Johns Hopkins University, MedImmune, LLC
    Inventors: Solomon Langermann, Linda Liu, Sheng Yao, Lieping Chen
  • Patent number: 9782428
    Abstract: Methods and composition for potentiating germinal centers are disclosed herein. The methods include potentiating germinal centers to enhance antibody production in response to a vaccine, to increase antibody titer in response to a vaccine, and to enhance B cell class switching.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: October 10, 2017
    Assignee: Northeastern University
    Inventors: Michail V. Sitkovsky, Robert Koehler Abbott, Stephen Matthew Hatfield
  • Patent number: 9770486
    Abstract: Disclosed are novel methods for preventing or attenuating neuronal damage or stimulating neuronal repair, prior to or following central nervous system injury associated with acute or chronic nervous system injury. Macrophage colony stimulating factor receptor agonists including macrophage colony stimulating factor (M-CSF or CSF-1), interleukin-34 (IL-34), proteins or biologically active fragments thereof, peptides or biologically active fragments thereof, peptidomimetics, or small molecules, and the like are effective for prevention or treatment of acute nervous system injury or chronic nervous system injury involving Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and the like.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: September 26, 2017
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Jian Luo, Anton Wyss-Coray
  • Patent number: 9771570
    Abstract: The present invention relates to isolated polypeptides having protease activity and isolated nucleic acid sequences encoding the proteases. The invention also relates to nucleic acid constructs, vectors, and host cells, including plant and animal cells, comprising the nucleic acid sequences, as well as methods for producing and using the proteases, in particular the use of the proteases in animal feed.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: September 26, 2017
    Assignee: Novozymes A/S
    Inventors: Mary Ann Stringer, Tine Hoff, Peter Rahbek Oestergaard, Katrine Pontoppidan
  • Patent number: 9745367
    Abstract: A method of selecting a genus of therapeutic antibodies includes selecting antibodies with the following criteria; a) do inhibit cell lysis under conditions wherein the alternative pathway is isolated from the classical pathway; and b) do not inhibit cell lysis under conditions wherein the classical pathway is isolated from the alternative pathway; and c) do not inhibit cell lysis under conditions wherein the classical pathway and alternative pathway are active; and d) do inhibit C3b produced exclusively by the alternative pathway.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: August 29, 2017
    Assignee: Novelmed Theraputics, Inc.
    Inventor: Rekha Bansal
  • Patent number: 9724413
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: August 8, 2017
    Assignee: Genentech, Inc.
    Inventors: Heather Maecker, Bryan Irving
  • Patent number: 9719981
    Abstract: The present invention provides methods of treating Alport syndrome in a subject by the administration of an agent that can block the activation of RAC1/CDC42 members of the rho family of small GTPases. Such agents include, but are not limited to, the endothelin receptor antagonists such as bosentan and letairis and neutralizing antibodies to endothelin-1. Such administration prevents invasion of the glomerular capillary tufts by mesangial lamellipodial/filopodial processes, blocks mesangial process invasion abrogates the deposition of laminin 211 in the GBM, and prevents the activation of maladaptive expression of proteins known to contribute to glomerular disease progression.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: August 1, 2017
    Assignee: Father Flanagan's Boys' Home
    Inventor: Dominic Cosgrove
  • Patent number: 9719135
    Abstract: This invention relates to the production and genotyping of mice lacking both Angiopoietin 1 and Angiopoietin 2. This invention also relates to the use of Tie2 receptor activation for treatment of open angle glaucoma, congenital glaucoma and cystic kidney disease, and more specifically to the use of angiopoietin 1 recombinant proteins, peptides, VE-PTP phosphatase inhibitors, and Tie2— peptomimetics to improve lymphatic drainage in the Schlemm's canal and corneal limbal lymphatic system for open angle glaucoma and congenital glaucoma patients, and to slow and/or reduce the growth of cysts in patients with cystic kidney disease.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: August 1, 2017
    Assignee: MANNIN RESEARCH INC.
    Inventor: Susan E. Quaggin
  • Patent number: 9708661
    Abstract: The present invention relates to methods, monitors and systems, useful, for example, for advanced detection of sepsis in a subject.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: July 18, 2017
    Assignee: Becton, Dickinson and Company
    Inventors: Song Shi, Richard L. Moore, James Garrett
  • Patent number: 9689039
    Abstract: Presented herein are biomarkers related to lung cancer. The presently identified salivary biomarkers create the basis for a lung cancer detection bioassay with sensitivity and specificity. Means and methods for evaluating the data generated using multiple biomarkers in order to validate findings and further use of the multiplexed lung cancer assay in clinical, diagnostic and therapeutic uses is also included.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: June 27, 2017
    Assignee: The Regents of the University of California
    Inventors: David T. Wong, Lei Zhang, Hua Xiao, Hui Zhou
  • Patent number: 9688746
    Abstract: The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: June 27, 2017
    Assignee: Canimguide Therapeutics AB
    Inventors: Leif Håkansson, Birgitta Clinchy
  • Patent number: 9683235
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: June 20, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Patent number: 9676856
    Abstract: Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of B7-H7 to B7-HrCR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. In another aspect, the therapeutic agents modulate the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. The therapeutic agents can be used in the prevention, treatment and/or management of diseases in which it might be useful to modulate one or more immune functions (e.g., cancer, infectious disease, autoimmune disease, and transplantation rejection). In another aspect, presented herein are methods for identifying receptor-ligand interactions.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: June 13, 2017
    Assignee: The Johns Hopkins University
    Inventor: Lieping Chen
  • Patent number: 9663580
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: May 30, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber, Martin Lanzendoerfer
  • Patent number: 9650438
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: May 16, 2017
    Assignee: Novartis AG
    Inventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Patent number: 9644003
    Abstract: The present invention relates to a RTN4B-related polypeptide, a monoclonal antibody thereof, a monoclonal antibody-producing hybridoma cell strain, and, preparation and applications thereof. The RTN4B polypeptide comprises an amino acid sequence presented by SEQ ID NO: 1. The invention further discloses a monoclonal antibody, a hybridoma cell strain to produce the monoclonal antibody prepared by the RTN4B polypeptide, and the related application in the treatment or prevention of tumors thereof.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: May 9, 2017
    Assignee: FUDAN UNIVERSITY
    Inventors: Long Yu, Guoqing Ji, Dingding Han, Yanhua Wu, Lisha Tang
  • Patent number: 9636334
    Abstract: Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: May 2, 2017
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Sarah L. Pogue, David S. Wilson, Anthony Gerard Doyle, Collette Jane Behrens
  • Patent number: 9637535
    Abstract: The present invention provides interleukin-33 (IL-33) antagonists comprising one or more IL-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the IL-33-binding domains can comprise an IL-33-binding portion of an ST2 protein and/or an extracellular portion of an IL-1RAcP protein. The IL-33 antagonists of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as infectious diseases, inflammatory diseases, allergic diseases and fibrotic diseases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 2, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Nicholas J. Papadopoulos, Jamie Orengo
  • Patent number: 9624285
    Abstract: A composition of matter is disclosed which comprises isolated oligomers of human islet amyloid polypeptide (IAPP). Antibodies recognizing same are also disclosed. Use of the composition of matter and the antibodies are also disclosed.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: April 18, 2017
    Assignee: Ramot a Tel-Aviv University Ltd.
    Inventors: Yaron Bram, Ehud Gazit
  • Patent number: 9617338
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: April 11, 2017
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • Patent number: 9605063
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: March 28, 2017
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
  • Patent number: 9594083
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 14, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Lorraine, Cantre Hospitalier et Universitaire de Nancy (CHU), Universite Paris Diderot-Paris 7, Universite Paris Descartes
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
  • Patent number: 9550828
    Abstract: A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: January 24, 2017
    Assignee: Boise State University
    Inventors: Cheryl Jorcyk, Dong Xu
  • Patent number: 9550829
    Abstract: The present invention relates to methods of treating liver cancer using a Notch signaling inhibitor. Compositions and methods for the treatment of liver cancers are also provided.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 24, 2017
    Assignee: Genentech, Inc.
    Inventors: Dorothy French, Erik Huntzicker, Christian W. Siebel
  • Patent number: 9533041
    Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: January 3, 2017
    Assignee: Institut National de la Santé et de la Recherche Médicale
    Inventor: Frédéric Jaisser
  • Patent number: 9512225
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: December 6, 2016
    Assignee: Yeda Research and Development Co. Ltd
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 9511117
    Abstract: The present invention provides methods for improving muscular function or treating a muscular disorder in an individual by administering to the individual a pharmacologically effective amount of a compound that inhibits microtubule-dependent NADPH Oxidase 2 reactive oxygen species signaling production. In addition compounds that block sarcolemmal Ca2+ channel activation and/or renin-angiotensin signaling may be administered with the inhibitor of microtubule-dependent NADPH Oxidase 2 reactive oxygen species signaling production.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: December 6, 2016
    Assignee: University of Maryland, Baltimore
    Inventors: Christopher W. Ward, Ramzi Khairallah